MedPath

Study to Investigate Effects of a Herbal Drug Compared to Placebo on Sleep

Phase 1
Completed
Conditions
Healthy
Sleep Quality
Interventions
Registration Number
NCT00997256
Lead Sponsor
Pascoe Pharmazeutische Praeparate GmbH
Brief Summary

To demonstrate the influence of a herbal preparation containing hypericum, passionflower, and valerian on sleep structure, improvement of attention, and well-being in comparison to placebo.

Detailed Description

To demonstrate the influence of the herbal combination preparation Neurapas® balance on the objective sleep structure in comparison with placebo. A further aim was to investigate whether treatment with Neurapas® balance versus placebo brings about an improvement in attention and well-being and whether these changes are related to the improvement in the sleep structure.

1. Does the administration of 3 x 2 Neurapas® balance tablets over a period of three days vs. placebo lead to an improvement in continuity of sleep?

2. Does the administration of 3 x 2 Neurapas® balance tablets over a period of three days vs. placebo lead to an improvement in sleep architecture, especially an increase in deep sleep?

3. Does the administration of 3 x 2 Neurapas® balance tablets over a period of three days vs. placebo lead to an improvement in morning attentional performance?

4. Does the administration of 3 x 2 Neurapas® balance tablets over a period of three days vs. placebo lead to an improvement in morning well-being?

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
20
Inclusion Criteria
  • Healthy male volunteers aged between 18 and 55 years
  • Normal sleeping times (at least 6 hours a night), going to sleep between 22.00 and 1.00 hours, getting up between 6.00 and 9.00 hours
  • Written informed consent
  • The volunteer is willing and able to cooperate fully
  • The volunteer agrees not to drink any alcohol for the duration of the study
Exclusion Criteria
  • Participation in another study in the last 30 days or participation in this study at an earlier date
  • Lack of verbal or intellectual ability to communicate adequately and to understand the information to volunteers
  • Legal incompetence
  • Smoker
  • Shift worker
  • Transatlantic flight in the last 4 weeks
  • Taking psychotropic drugs within the last 4 weeks
  • Taking medicines that influence the EEG within the last 4 weeks
  • Diseases that influence the sleep EEG
  • History of known medication / drug / alcohol misuse according to ICD-10 coding F10 - F19
  • Known intolerance/hypersensitivity/allergy to St. John's wort, valerian or passionflower
  • Taking inadmissible concomitant medication (anxiolytic, neuroleptic or hypnotic drugs, cyclosporin, sedative, sleep-promoting or mood-enhancing medicines, antidepressants other than the trial medication, coumarin-type anticoagulants, oral contraceptives, tranquillisers, homeopathic remedies, digoxin, theophylline, indinavir, nortriptyline, amitriptyline)
  • Known light-sensitivity

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
VerumNeurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))Neurapas balance, film-coated tablets
Placebofilm-coated sugar-pillFilm-coated sugar-pill
Primary Outcome Measures
NameTimeMethod
Evaluation of sleep by Polysomnography (sleep continuity and sleep architecture)Day 3 + 14
Secondary Outcome Measures
NameTimeMethod
Attention Stress Test d2 (Brickenkamp)Day 4 + 15
Alertness and vigilance test (TAP)Day 4 + 15
Trail-Making Test (TMT)Day 4 + 15
Questionnaire on physical symptoms of subjective well-Being(MKSL, Janke)Day 4 +15
Questionnaire on psychological aspects of well-being(BSKE, Janke)Day 4 + 15
ZERSSEN Scale of evaluation of subjective well-being (Bf-S)Day 4 + 15
Sleep Questionnaire(SF)Day 4 + 15

Trial Locations

Locations (1)

Phillipps University, Clinic for Psychiatry and Psychotherapy

🇩🇪

Marburg, Hesse, Germany

© Copyright 2025. All Rights Reserved by MedPath